2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. Pain
  5. Chronic Pain

Chronic Pain

Chronic pain is a persistent or recurrent painful condition lasting at least three months, extending beyond the normal healing period and not directly attributable to ongoing tissue damage. It is a complex syndrome influenced by biological, psychological, social, cultural, and environmental factors, characterized by an unpleasant sensory and emotional experience associated with actual or potential tissue injury. Chronic pain often persists after recovery from acute injury or illness, may have no identifiable cause, and significantly impacts physical function, emotional health, and quality of life across all age groups, with higher prevalence observed in older adults and women.

References:

Chronic Pain (9):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-142240
    Crisugabalin 2209104-84-5 99.88%
    Crisugabalin is an orally active, selective ligand for the α2δ subunit of voltage-gated calcium channels, with a target IC50 of 3.96 nM in rats. Crisugabalin inhibits the binding of [3H]gabapentin to the α2δ subunit, reduces calcium influx, decreases neuronal excitability, and impairs nociceptive transmission. Crisugabalin alleviates mechanical allodynia, neuropathic pain and inflammatory pain in rats, and reduces phase II pain behaviors. Crisugabalin can be used in research related to chronic pain, neuropathic pain, diabetic neuropathy, fibromyalgia, inflammatory pain, diabetic peripheral neuropathy and postherpetic neuralgia.
    Crisugabalin
  • HY-178698
    O-1812 342882-77-3
    O-1812 is a selective CB1 ligand. O-1812 is also a very weak AMT inhibitor. O-1812 can be used in the research of chronic pain, migraines, and inflammation.
    O-1812
  • HY-14406
    L-733060 148700-85-0
    L-733060 is a selective neurokinin-1 (NK-1) receptor antagonist. L-733060 mainly regulates pain transmission and neural plasticity by blocking the binding of Substance P (P substance) to the NK-1 receptor. L-733060 blocks the promoting effect of Substance P on long-term potentiation (LTP) in the hippocampus. L-733060 reverses the orofacial hyperalgesia induced by experimental occlusal interference (EOI) in rats. L-733060 hydrochloride inhibits neurogenic plasma extravasation at a dose that does not cause adverse cardiovascular effects in rodents, and also acts as an anti-tumor agent. L-733060 can be used for the study of chronic orofacial pain.
    L-733060
  • HY-180955
    Desfluoro-BMS-694153 773886-89-8
    Desfluoro-BMS-694153 (Compound 3) is a calcitonin gene-related peptide receptor (CGRP receptor) antagonist, with a Ki value of 0.01 nM. Desfluoro-BMS-694153 has a significantly reduced risk of CYP3A4 inhibition, and its IC50 values for CYP3A4-BFC and CYP3A4-BZR are 36 and 6 μM respectively. Desfluoro-BMS-694153 can be used for research on migraines.
    Desfluoro-BMS-694153
  • HY-148708A
    Oleoyl-D-lysine sodium
    Oleoyl-D-lysine sodium is a selective Glycine Transporter-2 (GlyT2) inhibitor based on lipid. Oleoyl-D-lysine sodium reverses neuropathic pain in mice, shows antidrowsiness effect on chronic neuropathic pain. Oleoyl-D-lysine sodium is safe and effective without respiratory depression.
    Oleoyl-D-lysine sodium
  • HY-171096
    PAR2 modulator-1 2378159-28-3
    PAR2 modulator-1 (Compound C781) is a protease activated receptor type 2 (PAR2) antagonist. PAR2 modulator-1 can specifically inhibit the PAR2-dependent MAPK signaling pathway with an IC50 value of 8.5 μM. PAR2 modulator-1 can block the pain response triggered by PAR2 agonists. PAR2 modulator-1 can be used for the researches of inflammation, immunology and neurological disease, such as chronic pain and asthma.
    PAR2 modulator-1
  • HY-115359
    BL-1021 1002331-76-1
    BL-1021 is an orally active ion channel blocker. BL-1021 significantly reduces symptoms of neuropathic pain without noticeable sedation or cardiac arrhythmias. BL-1021 can be used in the research of acute and chronic pain.
    BL-1021
  • HY-118646
    NS-6740 753500-02-6
    NS-6740 is a partial agonist of α7 nicotinic acetylcholine receptor (α7 nAChR) with an IC50 of 3 nM. NS-6740 also acts as a potent modulator of the cholinergic anti-inflammatory pathway. NS-6740 alters the signaling pattern of α7 in an ion channel-independent manner, thereby reducing synaptic function. NS-6740 induces the desensitized state of α7 nAChR. NS-6740 generates robust nAChR-mediated currents. NS-6740 reduces LPS (HY-D1056)-induced TNF-α release from microglia. NS-6740 can be used in the research of neuroinflammation and neuropathic pain.
    NS-6740
  • HY-101546A
    Cavidine 32728-75-9
    Cavidine ((+)-Cavidine) is an analgesic and anti-inflammatory agent. Cavidine can be isolated from Corydalis ternata f. yanhusuo (Y.H.Chou & Chun C.Hsu) Y.C.Zhu. Cavidine reduces the expression of inflammatory factors IL-1β, IL-6 and TNF-α, and inhibits calcium ion influx. Cavidine inhibits the phosphorylation of p38 and ERK1/2. Cavidine increases mechanical and thermal pain thresholds in chronic pain models. Cavidine can be used for the research of chronic pain.
    Cavidine